Recursion Pharmaceuticals (Recursion Pharmaceuticals) GF Score : 49/100 (As of May. 01, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Recursion Pharmaceuticals GF Score?

Recursion Pharmaceuticals has the GF Score of 49, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 4/10
5. Momentum Rank : 3/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Recursion Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Recursion Pharmaceuticals's GF Score

For the Biotechnology subindustry, Recursion Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recursion Pharmaceuticals's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's GF Score falls into.

Recursion Pharmaceuticals (NAS:RXRX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Recursion Pharmaceuticals GF Score Related Terms

Thank you for viewing the detailed overview of Recursion Pharmaceuticals's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101

Website

https://www.recursion.com

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Executives

Michael Secora	officer: Chief Financial Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani	officer: Chief Corp. Dev. Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson	director	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson	director, 10 percent owner, officer: Chief Executive Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson	officer: President and COO	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar	director	C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc	10 percent owner	P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert	other: Former 10% Owner	C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p.	other: Former 10% Owner	295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc	other: Former 10% Owner	920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc	other: Former 10% Owner	C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p.	other: Former 10% Owner	C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010